# A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

> **NCT07439653** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **TORL Biotherapeutics, LLC** · enrollment: 155 (estimated)

## Conditions studied

- Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** TORL-5-700
- **DRUG:** TORL-5-700 at MTD/RP2D
- **DRUG:** TORL-5-700 at MTD/RP2D in combination with another agent

## Key facts

- **NCT ID:** NCT07439653
- **Lead sponsor:** TORL Biotherapeutics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-30
- **Primary completion:** 2029-03-31
- **Final completion:** 2029-09-30
- **Target enrollment:** 155 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07439653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07439653, "A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07439653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*